Q-omics provides the consensus-scored BLOC1S2 profile across patient tissues and cancer cell-line models. BLOC1S2 expression is associated with patient survival in 22 of 34 cancer types, with the highest sampling consensus in ACC. Among the 18 cancer types available for tumor–normal comparison, BLOC1S2 is differentially expressed in 13, with the highest sampling consensus in KIRC. Additionally, BLOC1S2 protein abundance shows 20,141 significant protein co-abundance associations, with the highest sampling consensus in PDAC. Together, these results highlight ACC, KIRC, and PDAC as cancer lineages where BLOC1S2 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for BLOC1S2 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes BLOC1S2 survival associations across molecular data types. BLOC1S2 RNA expression shows survival associations in the most cancer types (22), followed by mutation status (1) and mass-spec protein abundance (5). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible BLOC1S2 RNA expression–survival associations across cancer types. High BLOC1S2 expression shows unfavorable associations in ACC, UVM, LAML, LIHC and HNSC, but favorable associations in LGG. The ACC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify ACC as the clearest survival context for BLOC1S2 RNA expression.
This table summarizes BLOC1S2 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 13, while mass-spec protein shows differences in 5. The strongest signals are observed in KIRC for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for BLOC1S2. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. BLOC1S2 shows higher tumor expression in KIRC, LIHC, KIRP, BLCA, HNSC and STAD. The KIRC box plot shows higher BLOC1S2 RNA expression in tumor versus normal tissue (log2 FC = +0.384, t-test p < 0.001).
This table shows molecular features associated with BLOC1S2 in patient tissues and cancer cell lines. In patient samples, BLOC1S2 shows the broadest associations at the RNA and protein expression levels, with PDAC recurring as the lineage with the largest associated feature set. In cancer cell lines, BLOC1S2 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BLOOD_Lymphoma, while CRISPR and shRNA rows add functional-dependency signals in LUNG_NSCLC_LUAD and UPPER_AERODIGESTIVE_TRACT.
